Nitrous Oxide, a Rapid Antidepressant, Has Ketamine-like Effects on Excitatory Transmission in Adult Hippocampus
Yukitoshi Izumi, F. Hsu, C. Conway, Peter Nagele, Steven Mennerick, Charles F Zorumski
Biological Psychiatry June 1, 2022 DOI: 10.1016/j.biopsych.2022.06.016 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical study Peer reviewed |
|---|---|
| Population | Hippocampal slices from adult albino rats |
| Interventions | Nitrous oxide Ketamine |
| Dose | 30% N2O for 15-20 min; 1 μM ketamine |
| Topics | Esketamine Ketamine |
| Key points | Nitrous oxide at a sub-anesthetic concentration produces persistent enhancement of AMPA and NMDA receptor-mediated synaptic transmission in the hippocampus, similar to ketamine but with some mechanistic differences. |
Abstract
Background: Nitrous oxide (N2O) is a non-competitive inhibitor of NMDA receptors (NMDARs) that appears to have ketamine-like rapid antidepressant effects in patients with treatment resistant major depression. In preclinical studies, ketamine enhances glutamate-mediated synaptic transmission in hippocampus and prefrontal cortex. The present study examined effects of N2O on glutamate transmission in hippocampus, and compared its effects to ketamine.
Methods: Glutamate-mediated synaptic transmission was studied in the CA1 region of hippocampal slices from adult albino rats using standard extracellular recording methods. Effects of N2O and ketamine at sub-anesthetic concentrations were evaluated by acute administration.
Results: Akin to 1 μM ketamine, 30% N2O administered for 15-20 min resulted in persistent enhancement of synaptic responses mediated by both AMPA receptors (AMPARs) and NMDARs. Synaptic enhancement by both N2O and ketamine was blocked by co-administration of a competitive NMDAR antagonist at saturating concentration, but only ketamine was blocked by an AMPAR antagonist. Synaptic enhancement by both agents involved tropomyosin receptor kinase B (TrkB), mechanistic target of rapamycin (mTOR), and nitric oxide synthase (NOS), with some differences between N2O and ketamine. N2O potentiation occluded enhancement by ketamine, and in vivo N2O exposure occluded further potentiation by both N2O and ketamine.
Conclusions: These results indicate that N2O has ketamine-like effects on hippocampal synaptic function at a sub-anesthetic, but therapeutically relevant concentration. These two rapid antidepressants have similar, but not identical mechanisms that result in persisting synaptic enhancement, possibly contributing to psychotropic actions.
Comparable studies
Other preclinical and animal studies on ketamine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Rats | 2010 | Observational study | |
| Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Conscious rats | 1997 | Dose-response study with microdialysis and behavioral testing | |
| NMDAR inhibition-independent antidepressant actions of ketamine metabolites Mice | 2016 | Preclinical study | |
| The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate Spinal neurons in decerebrate or pentobarbitone-anaesthetized cats and rats | 1983 | Experimental study | |
| R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects Mice | 2015 | Experimental study |
Citations in the library
Cited by 26
- NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine Journal of Neuroscience January 3, 2023
- Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment Neuropharmacology January 13, 2023
- Targeting metaplasticity mechanisms to promote sustained antidepressant actions. Molecular Psychiatry April 1, 2024
- Repurposing General Anesthetic Drugs to Treat Depression: A New Frontier for Anesthesiologists in Neuropsychiatric Care. Anesthesiology August 1, 2024
- Anesthetics as Treatments for Depression: Clinical Insights and Underlying Mechanisms. Annual Review of Neuroscience February 19, 2025
and 21 more in the library
Cites 24
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Science August 19, 2010
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature April 24, 2016
- Ketamine: a paradigm shift for depression research and treatment Neuron March 1, 2019
- GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions. Journal of Clinical Investigation November 19, 2019
and 19 more in the library